⌕
Sarepta Therapeutics · SRPT · Nasdaq
Tenet 48 · Mixed
Compare
$14.77−2.38%At closeTenet 48 · Mixed
$14.77−0.36 (−2.38%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Sarepta Therapeutics (SRPT) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice

18 figures withheld by our checks. Each blank figure names its reason.

Business engineGrowing fast: revenue compounds ~33.0%/yr (FY21→FY25), net margin −32.5%. Worth your attention in FY25: Share count (+23.2%) and Returns vs FCF (n/m). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲15.6%
2,198.2
FY21→FY25CAGR +33.0%/yr
Net income ($M)—
−713.4
one-off year: see footnoteCAGR —
Free cash flow ($M)▲10.3%
−307.5
FY21→FY25CAGR —
Diluted EPS—
−7.13
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+23.2%

81.3mn → 100.1mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex
$102.0M

−25.5% YoY in FY25 · 4.6% of revenue.

Returns vs FCF
n/m

$27.4M returned vs $−307.5M of FCF in FY25. Free cash flow was negative, so returns were funded from the balance sheet rather than from cash generation.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)2198.2Revenue0.0COGS−1522.1R&D−491.7SG&A−699.8Op income−13.6Tax & other−713.4Net income

-32¢ of every revenue dollar becomes profit.

Margin trend · direction beats level Gross Operating Net
1007550250%sector median net margin ~3%FY21FY25

Net margin -32.5% is below the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
1,956,339.02,198,237.01,901,979.01,243,336.0933,013.0701,887.0▲15.6%+33.0%
Cost of revenue
—0.00.00.00.00.0——
Gross profit
—A—A—A—A—A701,887.0——
Research & development
653,103.01,522,066.0804,522.0877,387.0877,090.0771,182.0▲89.2%+18.5%
Selling, general & admin
463,460.0491,716.0557,872.0481,871.0451,421.0282,660.0▼11.9%+14.8%
Total operating expenses
2,005,238.02,898,018.01,683,898.01,511,160.01,469,214.01,161,597.0▲72.1%+25.7%
Operating incomefeeds ROC rank
−48,899.0−699,781.0218,081.0−267,824.0−536,201.0−459,710.0——
Other income, net
−43,117.0−2,444.042,693.0−252,274.0−153,762.040,762.0——
Pretax income
−92,016.0−702,225.0260,774.0−520,098.0−689,963.0−418,948.0——
Income tax
22,602.011,185.025,535.015,879.013,525.0−168.0▼56.2%−6.1% (22→25)
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−114,618.0−713,410.0235,239.0−535,977.0−703,488.0−418,780.0——
Per share
Diluted EPSbuyback-sensitive
−1.36−7.132.34−5.80−8.03−5.15——
Diluted shares (mn)
105.93100.12107.8892.4087.5681.26▼7.2%+5.4%
Margins
Gross margin
—A—A—A—A—A100.0%——
Operating margin
−2.5%−31.8%11.5%−21.5%−57.5%−65.5%▼43.3pp+33.7pp
Net margin18th pct in Healthcare
−5.9%−32.5%12.4%−43.1%−75.4%−59.7%▼44.8pp+27.2pp
† TTM = trailing four quarters through 2026-09-30.FY24 effective tax rate was 10% vs a −2% norm for this window, likely a one-time item; see the filing.A Withheld: cost of revenue is not on file, so the gross margin is not measured.
FY09 – FY20 · 12 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 12 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-03-02 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Sarepta Therapeutics' revenue last fiscal year?

Sarepta Therapeutics reported revenue of $2,198.2M in fiscal 2025, up 15.6% from fiscal 2024.

What was Sarepta Therapeutics' net income?

Sarepta Therapeutics reported net income of −$713.4M in fiscal 2025, a net margin of −32.5%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.